Read more

October 27, 2021
5 min watch
Save

VIDEO: Prostate cancer screening tool shows promise

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video Sandeep Gurram, MD, a urologic oncologist at the National Cancer Institute in Bethesda, Maryland, discusses a study on the novel diagnostic tool, the miR Sentinel PCC4 Test, presented at the American Urological Association's annual meeting.

The study, which found that the test was an accurate noninvasive way to screen for prostate cancer, with a negative predictive value of 96%.

"The original assessment shows very positive results in that there is a 98% sensitivity and a 96% specificity, and we are distinguishing between clinically insignificant disease in Gleason grade group 1 or lower and clinically significant disease," Gurram said.